RxDoctor Payments Data

Will Heise, MD

Family Medicine · Choctaw, OKNPI 1962840504

Payments from drug & device makers

$3,256in general payments, 2019–2025

Across 195 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$979
  • AstraZeneca$741
  • GSK$392
  • Lilly USA, LLC$307
  • Novo Nordisk$213
  • Pfizer$118
  • plus $507 from 10 others

What the payments were for

  • Food & beverage$3,250100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,256 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$134,297
Medicare patients
593
Services billed
2,669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$147,479
OzempicSemaglutide82$126,781
EliquisApixaban104$112,886
TrulicityDulaglutide45$70,221
JardianceEmpagliflozin68$67,156
MounjaroTirzepatide20$46,766
FarxigaDapagliflozin Propanediol30$32,620
LinzessLinaclotide29$25,417
MyrbetriqMirabegron13$23,627
JanuviaSitagliptin Phosphate11$17,954
Spiriva HandihalerTiotropium Bromide25$13,133
XareltoRivaroxaban14$13,031
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,811
Tresiba Flextouch U-100Insulin Degludec15$9,769
Advair HfaFluticasone Propion/Salmeterol14$7,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$392$158,289143 claims
Novo NordiskOzempic$213$126,78182 claims
Lilly USA, LLCTrulicity, Mounjaro$307$116,98765 claims
PfizerEliquis$118$112,886104 claims
Boehringer IngelheimJardiance, Tradjenta$85$73,49880 claims
AstraZenecaFarxiga$741$32,62030 claims
AbbVieLinzess$979$25,41729 claims
MerckJanuvia, Lagevrio (Eua)$13$23,50824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Choctaw

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →